RPA2 and prostate carcinoma: PCAT19 has been reported to safeguard DNA in quiescent endothelial cells by preventing uncontrolled phosphorylation of replication protein A2 (RPA2) [53], is implicated in driving prostate cancer [54], and has served as a prognostic biomarker for endometrial cancer [55].